Bioseutica B.V.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Bioseutica B.V. - overview
Established
1947
Location
-, -, Netherlands
Primary Industry
Biotechnology
About
Bioseutica B. V. is a Netherlands-based company specializing in the production of natural source ingredients, primarily focusing on enzymes and proteins derived from eggs and pancreatic sources. Founded in 1947 and headquartered in the Netherlands, Bioseutica B.
V. produces high-quality natural ingredients used in various industries. The firm operates without any known subsidiaries or parent companies and has not undergone any reported changes in its business strategy since its inception. Bioseutica® specializes in the production of natural source ingredients, focusing primarily on enzymes and proteins derived from eggs and pancreatic sources.
Their core product offerings include lysozyme, avidin, and ovotransferrin, which are utilized for their potent antimicrobial properties across various industries such as food processing, pharmaceuticals, and animal health. These products are designed to enhance food safety, extend shelf life, and improve quality while also addressing specific needs in infant nutrition and livestock health. Bioseutica® serves a diverse client base that includes manufacturers in the USA, China, and Europe, providing them with non-GMO, ultrapure bioactive proteins and functional foods. The company is committed to sustainability and innovation, producing solutions that not only meet industry demands but also align with global health and environmental standards.
In 2022, Bioseutica® generated a revenue of USD 24. 33 mn with an EBITDA of USD -1. 57 mn. The company employs a B2B model, supplying its products directly to manufacturers in the food, pharmaceutical, and feed industries, primarily through bulk sales agreements tailored to meet client needs.
Bioseutica® is strategically positioned for future growth, focusing on the development of new products aimed at enhancing its enzyme and protein offerings. The company plans to expand into the Asian and North American markets by the end of 2024. Recent funding will support these initiatives, enabling the launch of innovative products and the establishment of a stronger presence in these target regions.
Primary Industry
Biotechnology
Sub Industries
Food, Biotechnology, Pharmaceuticals
Website
www.bioseutica.com
Total Amount Raised
Subscriber access only
Bioseutica B.V. - timeline of key events
Bioseutica B.V. - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 27,250,000 | 23,153,000 | 23,033,000 | 24,283,000 | 20,223,000 | 20,093,000 | 20,862,000 | 19,922,000 | - | - | - |
| % Revenue Growth (YoY) | - | (15.0%) | (0.5%) | 5.4% | (16.7%) | (0.6%) | 3.8% | (4.5%) | - | - | - |
| EBITDA (USD) | (1,617,000) | 1,826,000 | 2,229,000 | 4,516,000 | 3,959,000 | 1,946,000 | 2,865,000 | 1,152,000 | - | - | - |
| Operating Income (USD) | (2,714,000) | 892,000 | 1,227,000 | 3,546,000 | 3,097,000 | 1,026,000 | 1,562,000 | (145,000) | - | - | - |
| Operating Margin | (10.0%) | 3.9% | 5.3% | 14.6% | 15.3% | 5.1% | 7.5% | (0.7%) | - | - | - |
| % EBITDA Margin | (5.9%) | 7.9% | 9.7% | 18.6% | 19.6% | 9.7% | 13.7% | 5.8% | - | - | - |
| NET Income (USD) | 3,609,000 | 7,574,000 | 1,052,000 | 3,567,000 | 843,000 | 1,269,000 | 434,000 | (400,000) | - | - | - |
| % Net Margin | 13.2% | 32.7% | 4.6% | 14.7% | 4.2% | 6.3% | 2.1% | (2.0%) | - | - | - |
Bioseutica B.V. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | KD Pharma Group SA | - |
Displaying 1 - 1 of 1
Bioseutica B.V. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.